Compound Evidence File
#EC-2026-0656
1-Boc-4-(2-fluorophenylamino)piperidine CAS 887583-57-5
Filed under Raw Materials. The bureau holds 106 laboratory returns for this compound from 40 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
40 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 6 | 10.0 | 9.9 | 10.0 | 23 May 2026 | 23 May 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 4 | 10.0 | 9.9 | 10.0 | 6 Feb 2026 | 12 Jun 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 3 | 10.0 | 9.9 | 10.0 | 4 Feb 2026 | 6 Jul 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 3 | 10.0 | 10.0 | 10.0 | 1 May 2026 | 4 Jul 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 3 | 10.0 | 9.9 | 10.0 | 14 Jan 2026 | 18 Jun 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 3 | 10.0 | 10.0 | 10.0 | 3 Apr 2026 | 10 Jun 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 3 | 10.0 | 9.9 | 10.0 | 17 May 2026 | 3 Jul 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 3 | 10.0 | 10.0 | 10.0 | 25 Feb 2026 | 15 Jul 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 3 | 10.0 | 9.9 | 10.0 | 6 May 2026 | 3 Aug 2026 |
| SinoPepCASE #VI-2026-0387 | A | 3 | 10.0 | 9.9 | 10.0 | 9 Feb 2026 | 11 Aug 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 2 | 10.0 | 10.0 | 10.0 | 16 Jun 2026 | 10 Jul 2026 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 7 | 9.9 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 4 | 9.9 | 9.9 | 10.0 | 1 Jun 2026 | 14 Jul 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 3 | 9.9 | 9.9 | 10.0 | 9 Jan 2026 | 5 Apr 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 3 | 9.9 | 9.9 | 10.0 | 20 Jan 2026 | 27 Apr 2026 |
| BachemCASE #VI-2026-0314 | A | 2 | 9.9 | 9.9 | 10.0 | 6 Jul 2026 | 7 Jul 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 2 | 9.9 | 9.9 | 10.0 | 7 Feb 2026 | 1 May 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 2 | 9.9 | 9.9 | 9.9 | 8 Nov 2025 | 26 Mar 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 2 | 9.9 | 9.9 | 9.9 | 23 Mar 2026 | 19 May 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 2 | 9.9 | 9.9 | 9.9 | 6 May 2026 | 18 May 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 2 | 9.9 | 9.9 | 10.0 | 11 Jul 2026 | 27 Jul 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 2 | 9.9 | 9.9 | 10.0 | 20 Jun 2026 | 23 Jul 2026 |
| AsymchemCASE #VI-2026-0091 | A | 2 | 9.9 | 9.9 | 10.0 | 10 Jul 2026 | 15 Jul 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 3 | 9.3 | 8.6 | 10.0 | 24 May 2026 | 24 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 5 | 9.1 | 8.2 | 10.0 | 23 May 2026 | 23 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 4 | 8.5 | 6.6 | 10.0 | 24 May 2026 | 24 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 6 | 8.4 | 6.9 | 9.8 | 25 May 2026 | 25 May 2026 |
| Peptide TechnologiesCASE #VI-2026-0694 | X | 1 | 8.2 | 8.2 | 8.2 | 13 Feb 2025 | 13 Feb 2025 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 3 | 8.1 | 7.2 | 9.0 | 24 May 2026 | 24 May 2026 |
| TSC Top Supplements ChinaCASE #VI-2026-0523 | X | 1 | 7.7 | 7.7 | 7.7 | 13 Jun 2025 | 13 Jun 2025 |
| Xingtai Jiachuang TechnologyCASE #VI-2026-0712 | X | 2 | 7.2 | 6.6 | 7.9 | 17 Dec 2024 | 24 May 2026 |
| HealthTide BiotechCASE #VI-2026-0955 | X | 1 | 7.0 | 7.0 | 7.0 | 17 Dec 2024 | 17 Dec 2024 |
| Zen PeptidesCASE #VI-2026-0940 | X | 1 | 6.6 | 6.6 | 6.6 | 2 Apr 2025 | 2 Apr 2025 |
| Peptide CraftersCASE #VI-2026-0994 | X | 2 | 6.2 | 5.6 | 6.7 | 24 Apr 2025 | 24 May 2026 |
| Golden EagleCASE #VI-2026-0680 | X | 1 | 6.1 | 6.1 | 6.1 | 2 Jul 2025 | 2 Jul 2025 |
| Biolongevity LabsCASE #VI-2026-0442 | X | 1 | 5.9 | 5.9 | 5.9 | 25 Apr 2025 | 25 Apr 2025 |
| Amino AmigosCASE #VI-2026-0061 | X | 3 | 5.5 | 2.5 | 7.1 | 20 Jun 2025 | 20 May 2026 |
| Huaian Hanyou PeptideCASE #VI-2026-0297 | X | 1 | 4.7 | 4.7 | 4.7 | 27 Feb 2025 | 27 Feb 2025 |
| PepKitsCASE #VI-2026-0320 | X | 1 | 0.2 | 0.2 | 0.2 | 17 Dec 2024 | 17 Dec 2024 |
| SubQ SocietyCASE #VI-2026-0716 | X | 1 | 0.1 | 0.1 | 0.1 | 2 Jul 2025 | 2 Jul 2025 |
Open any subject to view the batch-level evidence for 1-Boc-4-(2-fluorophenylamino)piperidine CAS 887583-57-5 alone.